Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Optimal levels of vaccination to reduce COVID-19 infected individuals and deaths: A global analysis

Mario Coccia

CNR – National Research Council of Italy, Collegio Carlo Alberto, Via Real Collegio, n. 30, 10024, Moncalieri, TO, Italy

ABSTRACT

Coronavirus disease 2019 (COVID-19) continues to be a pandemic threat that is generating a constant state of alert in manifold countries. One of the strategies of defense against infectious diseases (e.g., COVID-19) is the vaccinations that decrease the numbers of infected individuals and deaths. In this context, the optimal level of vaccination for COVID-19 is a basic point to control this pandemic crisis in society. The study here, using data of doses of vaccines administered per 100 inhabitants, confirmed cases and case fatality ratio of COVID-19 between countries (N = 192) from March to May 2021, clarifies the optimal levels of vaccination for reducing the number of infected individuals and, consequently, the numbers of deaths at global level. Findings reveal that the average level of administering about 80 doses of vaccines per 100 inhabitants between countries can sustain a reduction of confirmed cases and number of deaths. In addition, results suggest that an intensive vaccination campaign in the initial phase of pandemic wave leads to a lower optimal level of doses administered per 100 inhabitants (roughly 47 doses of vaccines administered) for reducing infected individuals; however, the growth of pandemic wave (in May, 2021) moves up the optimal level of vaccines to about 90 doses for reducing the numbers of COVID-19 related infected individuals. All these results here could aid policymakers to prepare optimal strategies directed to a rapid COVID-19 vaccination rollout, before the takeoff of pandemic wave, to lessen negative effects of pandemic crisis on environment and socioeconomic systems.

1. Goals of the investigation

Coronavirus disease 2019 (COVID-19) is an infectious illness caused by the novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which appeared in late 2019 (Anand et al., 2021; Bontempi et al., 2020, 2021; Bontempi and Coccia, 2021; Coccia, 2020, 2020a, 2021). COVID-19 is still circulating in 2021 with mutations of the novel coronavirus that generate continuous COVID-19 infections and deaths in manifold countries (Johns Hopkins Center for System Science and Engineering, 2021; Huang et al., 2021; National Academy of Medicine, 2021; Vicenti et al., 2021). Seligman et al. (2021) show some characteristics of people that are associated with COVID-19 mortality, such as: mean age of 71.6 years, nonwhite race/ethnicity, income below the median and less than a high school level of education. High numbers of COVID-19 related infected individuals and deaths worldwide have supported the development of different types of vaccines based on viral vector, protein subunit and nucleic acid-RNA (Abbasi, 2020; de Vlas and Coffeng, 2021; Jones and Helmreich, 2020). In vector vaccines, genetic material from the COVID-19 virus is placed in a modified version of a different virus (called, viral vector). When the viral vector gets into human cells, it delivers genetic material from the COVID-19 virus directed to instruct the cells to make copies of the Spike (S) protein (the main protein used as a target in COVID-19 vaccines). After that, human cells display the S proteins on their surfaces and immune system responds by creating antibodies and defensive white blood cells to fight the novel coronavirus (viral vector vaccines for COVID-19 are by Janssen/Johnson & Johnson and University of Oxford/AstraZeneca). Protein subunit vaccine includes only the parts of a virus that best stimulate immune system. This type of COVID-19 vaccine has harmless S proteins. The immune system recognizes S proteins and creates antibodies and defensive white blood cells to fight the viral agent (Novavax, an American biotechnology company, has developed this type of protein subunit vaccine; cf., GAVI, 2021). Instead, the messenger Ribonucleic acid (mRNA) vaccines use genetically engineered mRNA to give to cells

https://doi.org/10.1016/j.envres.2021.112314

Received 17 June 2021; Received in revised form 26 October 2021; Accepted 28 October 2021

Available online 2 November 2021

0013-9351/© 2021 Elsevier Inc. All rights reserved.
instructions on how to make the S protein found on the surface of the SARS-CoV-2, creating antibodies to fight this novel coronavirus (Mayo Clinic, 2021). The process of development of mRNA vaccines for COVID-19 is much faster than conventional vaccines to be redesigned and mass-produced (Cylus et al., 2021; Heaton, 2020; Jeyananth et al., 2020; Komaroff, 2020). The first path-breaking mRNA vaccines for COVID-19 are due to premier biopharmaceutical companies: Pfizer-BioNTech and Moderna (cf., Coccia, 2015, 2017, 2017c, 2020c, 2021a). The investigation of vaccination plans between countries is a crucial aspect to determine how the novel infectious disease can be controlled and/or eradicated in the population (Aldila et al., 2021). Vaccination has the potential effect to reduce the diffusion of COVID-19, to relax non-pharmaceutical measures and maintain low basic reproduction number, but an important point is to clarify the levels of administering of vaccines between countries to timely reduce negative effects in society (Anser et al., 2020). Akamatsu et al. (2021) argue the vital role of governments to implement an efficient campaign of vaccination to substantially reduce infections in society, and avoid the collapse of healthcare system (cf., Coccia, 2021a, 2022; Aldila et al., 2021) maintain that higher levels of vaccination rate can eradicate COVID-19 in population by approaching herd immunity to protect vulnerable individuals (cf., Anderson et al., 2020; Randolph and Barreiro, 2020). Herd immunity indicates that only a share of population needs to be immune and therefore no longer susceptible to a viral agent (by overcoming natural infection or through vaccination) for controlling large outbreaks (Fontanet and Cauchemez, 2020). Scholars estimate the proportion of a population that needs to be vaccinated to support herd immunity, *ceteris paribus* (Redwan, 2021). The threshold level depends on basic reproduction number, *R₀*— the number of average cases spawned by one infected individual in an otherwise fully susceptible (Coccia, 2020; Kwok et al., 2020). In particular, the formula for calculating the herd-immunity threshold is 1/1-R₀ and it indicates that the more people who become infected by everyone who has the virus, the higher the proportion of the population that needs to be immune to reach herd immunity. The index *R₀* assumes that everyone is susceptible to the virus, but the level changes as the epidemic evolves, since it depends on changes in susceptibility of the population, mitigation and restriction policies, circulation of variants, etc. (Aschwanden, 2020, 2021; Coccia, 2021c, 2021d). In addition, the relax of mitigation and containment measures can move up herd-immunity threshold in specific situation (Buss et al., 2021; Dashbali and Mirzaie, 2021). Kwok et al. (2021) argue that the estimates of effective reproduction number range from 1.06 to 6.64 and the minimum proportion (%) of total population required to confer COVID-19 immunity is 5.66 in Kuwait and 85 in Bahrain. Rosen et al. (2021) describe socioeconomic and organizational factors associated with the vaccination campaign in Israel, a virtuous country in the plan of vaccination for COVID-19 (cf., Prieto Cruriel et al., 2021).

In this context, a fundamental problem in COVID-19 pandemic crisis is the optimal level of vaccination that supports a drastic reduction of COVID-19 infected individuals and deaths. The present study confronts this problem here by developing a statistical analysis to explain, at global level, different optimal levels of vaccination, during the evolution of COVID-19 pandemic wave, that trigger a reduction of infected individuals in society. Results can suggest best practices for vaccination plans to guide effective and timely policy responses for constraining negative effects of COVID-19 pandemic crisis and future epidemics of similar infectious diseases in environment and socioeconomic systems. This study is part of a large research project directed to explain drivers of transmission dynamics of COVID-19 and design effective policy responses to cope with and/or to prevent pandemic threats in society (Coccia, 2020b, 2021b, 2021e, 2021h, 2021i, 2022a).

## 2. Materials and methods

### 2.1. Source and sample

The sample of this study is *N* = 192 countries worldwide. Period under study is from March to May 2021, using data of vaccines, confirmed cases and case fatality ratio of COVID-19. The list of countries under study is in Appendix A.

- **Measures**
  - Doses of vaccines administered × 100 inhabitants on March 1, April 1 and May 1, 2021.
  
  Doses of vaccines refer to the total number of vaccine doses, considering that an additional dose may be obtained from each vial (e.g., six doses for Pfizer BioNTech® Comirnaty), whereas number of doses administered refers to any individual receiving any dose of the vaccine (cf., Freed et al., 2021; Oliver et al., 2020). The data here considers all types of COVID-19 vaccines used in different countries, i.e., vaccines by Johnson & Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V and Moderna (Ritchie et al., 2020). Of course, every country has been using a different combination of these COVID-19 vaccines to protect the population (CBC, 2021; CDC, 2021; Rossman et al., 2021). Source: Our World in Data (2021).
  
  - Number of COVID-19 infected individuals (%) is measured with confirmed cases of COVID-19 (on March 21, April 21 and May 21, 2021) divided by population of countries under study. This study considers a time lag of 21 days from doses of vaccines administered (1st day of the month) to confirmed cases of COVID-19 (21 day of the same month) to assure a certain level of protection in population that begins after a variable number of days (Faes et al., 2020; Zhang et al., 2020). Source of data: Johns Hopkins Center for System Science and Engineering (2021).
  
  - Number of COVID-19 deaths is measured with Case Fatality Ratio % (on March 21, April 21 and May 21, 2021). It indicates the severity of an infectious disease and evaluates the quality of health systems (Coccia, 2021e; Lau et al., 2021; WHO, 2020; Wilson et al., 2020). Case Fatality Ratio (CFR) estimates the proportion of deaths among identified confirmed cases of COVID-19:

\[
\text{CaseFatalityRatio (CFR)} \% = \left( \frac{\text{NumberofdeathsfromCOVID}-19}{\text{NumberofconfirmedcasesofCOVID}-19} \right) \times 100
\]

Angelopoulos at al. (2020) maintain that Case Fatality Ratios (CFRs) between countries are critical measures of relative risk that guide policymakers to decide how to allocate medical resource to cope with COVID-19 pandemic crisis. This study also calculates the mortality rate per 100 000 people for a comparative analysis with CFRs to assess the effects of vaccination with two indexes. Source of data: Johns Hopkins Center for System Science and Engineering (2021).

### 2.2. Model and data analysis procedure

Firstly, data are analyzed with descriptive statistics of variables given by arithmetic mean and standard error of the mean. Data concerning doses of COVID-19 vaccines, confirmed cases and CFR in the dataset downloaded the days under study can refer to data of different days because of difficulties in countries associated with gather or transmission of information. Moreover, database here includes different COVID-19 vaccines having a different period of administering between the first and second dose to provide a certain level of protection that begins after a variable number of days (approximately after 10–15 days the first dose) and remains for some months (about six months). In the presence of this just mentioned issue, the study here considers a time lag
of 21 days from date of doses of vaccines and date of confirmed cases. In addition, this study considers a large sample of N = 192 countries having a normal distribution that mitigates discrepancies among countries for significant statistical analyses.

We assume different scenarios considering the evolution of COVID-19 pandemic wave and vaccination over time and countries:

- **Scenario A.** Initial stage of COVID-19 pandemic wave in March 2021. If countries of the sample have the level of vaccination at the time t (March 1, 2021) and confirmed cases at t+21 days (March 21, 2021), how would be the optimal level of doses of vaccines administered.
- **Scenario B.** Maturity stage of COVID-19 pandemic wave in May 2021. If countries of the sample have the level of vaccination at the time t' (May 1, 2021) and confirmed cases of t' + 21 days (May 21, 2021), how would be the optimal level of doses of vaccines administered.
- **Scenario C.** Overall evolution of COVID-19 pandemic wave from March to May to estimate the optimal level of doses of vaccines administered between countries.

**Secondly,** the analysis of simple regression applies quadratic models because they fit the scatter of data to detect nonlinear effects of relations understudy.

The specification of model for three scenarios just described is given by:

\[ y_{it} = \alpha_0 + \beta_1 x_{it-21} + \beta_2 x_{it-21}^2 + \epsilon_{it} \]  

[1]

where:
- \( x_{it-21} \) = Doses of vaccines administered \( \times 100 \) inhabitants on 1st day of the month (Explanatory variable)
- \( y_{it} \) = Number of confirmed cases of COVID-19 on 21st day of the month (Response or dependent variable)
- \( \epsilon_{it} \) = Error term
- country \( i = 1, \ldots, n; \) t = time

Remark 1. The square of the doses of vaccines administered \( \times 100 \) inhabitants in model [1] is introduced to consider the possibility of nonlinear effects in the relation understudy.

Remark 2. Model [1] has a time lag effect between explanatory (\( +21 \) days) and dependent variables (\( t \)) to reduce the endogeneity of explanatory variable in model and provide reliable (estimated) parameters.

**Thirdly,** the optimization of the estimated relationships [1] is performed with the perspective of maximization of equation [1] to find the optimal levels of doses of vaccines administered \( \times 100 \) inhabitants (during the cycle of evolution of the COVID-19 pandemic) that support a consequential drastic reduction of confirmed cases of COVID-19 and negative effects in society. In particular, the estimated relationships [1] for three scenarios (A, B, and C) are objective functions of one (real) variable given by polynomial functions of second order. These estimated relations [1] are continuous and infinitely differentiable functions. The calculus applied on functional relation [1] provides the optimal levels of doses of vaccines administered \( \times 100 \) inhabitants that reduce, subsequently, confirmed cases between countries in a specific stage of COVID-19 pandemic wave as described in scenarios A, B, and C.

Finally, the optimal doses of vaccines administered, calculated as described in previous statistical and mathematical analyses, are used as cut-off points. In particular, average Case Fatality Rates (%) and Mortality rates per 100 000 people are calculated for countries having lower or higher levels of doses of vaccines than cut-off points (i.e., optimal estimated values). This analysis also considers the population of countries in 2020 to assess if the size of countries plays a role in the policy responses to cope with COVID-19 pandemic crisis.

Statistical analyses are performed with the Statistics Software SPSS® version 26.

3. Results

**Table 1** shows descriptive statistics of variables in March, April and May 2021.

□ **Scenario A.** Initial phase of COVID-19 pandemic wave in March 2021.

The estimated relationship, based on results of Table 2, is:

\[ z_{it} = 3.25 + 0.187 h_{i, t-21} - 0.002 h_{i, t-21}^2 \]

The polynomial function is given by:

\[ z = 3.25 + 0.187 h - 0.002 h^2 \]

the necessary condition to maximize is:

\[ \frac{dz}{dh} = z'(h) = 0.187 - 0.004h = 0 \]

The first derivative equal to 0 is:

\[ z'(h) = 0 \Rightarrow h^* = \frac{0.187}{0.004} = 46.75 \text{doses of vaccines per 100 inhabitants in March 2021} \]

\( h^* = 46.75 \text{ doses of vaccine per 100 people; } h^* \) indicates the optimal level in the initial phase of pandemic wave (March 2021) between countries to trigger a sharply decrease of confirmed cases and diffusion of COVID-19 leading, whenever possible, to constraint negative effects of the pandemic crisis in society.

□ **Scenario B.** Maturity phase of COVID-19 pandemic wave in May 2021.

The estimated relationship, based on results of Table 3, is:

\[ y_{it} = 1.45 + 0.180 x_{it-21} - 0.001 x_{it-21}^2 \]

The function is given by:

\[ y = 1.45 + 0.180x - 0.001x^2 \]

the necessary condition to maximize the function is:

\[ \frac{dy}{dx} = y'(x) = 0.180 - 0.002x = 0 \]

The first derivative equal to 0 is:

\[ y'(x) = 0 \Rightarrow x^* = \frac{0.180}{0.002} = 90 \text{doses of vaccines per 100 inhabitants in May 2021} \]

\( x^* = 90 \text{ doses of vaccines per 100 people; } x^* \) indicates the optimal level during the phase of maturity of the COVID-19 pandemic in May 2021

| Table 1 | Descriptive statistics, N=192 countries worldwide. |
|---|---|---|
| Variables | Mean | Std. Error |
| Doses vaccines per 100 inhabitants March 1, 2021 | 7.547 | 1.506 |
| Doses vaccines per 100 inhabitants April 1, 2021 | 12.750 | 1.573 |
| Doses vaccines per 100 inhabitants May 1, 2021 | 19.514 | 1.957 |
| Confirmed Cases/population % March 21, 2021 | 2.640 | 0.234 |
| Confirmed Cases/population % April 21, 2021 | 3.062 | 0.265 |
| Confirmed Cases/population % May 21, 2021 | 3.421 | 0.288 |
| Case Fatality Rate % March 21, 2021 | 2.182 | 0.186 |
| Case Fatality Rate % April 21, 2021 | 2.138 | 0.176 |
| Case Fatality Rate % May 21, 2021 | 2.271 | 0.215 |
| Mortality rates per 100 000 people March 21, 2021 | 51.131 | 4.773 |
| Mortality rates per 100 000 people April 21, 2021 | 58.046 | 5.369 |
| Mortality rates per 100 000 people May 21, 2021 | 63.443 | 5.741 |
between countries to support, after this threshold, a sharply decrease of infections that reduces negative effects of COVID-19 pandemic in society.

**Scenario C**: Overall evolution of COVID-19 pandemic from March to May 2021 between countries

The estimated relationship, based on results of Table 4, is:

\[ j_{w} = 2.33 + 0.161w - 0.001w^2 \]

The function is given by:

\[ j = 2.33 + 0.161w - 0.001w^2 \]

the necessary condition to maximize the function is:

\[ \frac{dj}{dw} = j'(w) = 0.161 - 0.002w = 0 \]

The first derivative equals to 0 is:

\[ j'(w) = 0 \Rightarrow w^* = \frac{0.161}{0.002} = 80.5 \text{ doses of vaccine per 100 inhabitants} \]

Table 2

Regression analyses of confirmed cases of March 21, 2021 on doses of vaccines on March 1, 2021 based on quadratic model [1].

| Constant $\alpha$ (St. Err.) | 3.25 *** (.47) |
|-----------------------------|----------------|
| Coefficient $i_1$ (St. Err.) | .187 ** (.07) |
| Coefficient $i_2$ (St. Err.) | −.002* (.001) |
| $R^2$ (St. Err. of Estimate) | .10 (3.24) |
| $F$                           | 4.79**         |
| Total cases                  | 192            |

Note: Dependent variable is: Confirmed cases/population (%) of March 21, 2021. Explanatory variable is: doses of vaccines per 100 inhabitants on March 1, 2021.

Significance: *** p-value < 0.001, ** p-value < 0.01, * p-value < 0.05.

Table 3

Regression analyses of confirmed cases (%) of May 21, 2021 on doses of vaccines on May 1, 2021 based on quadratic model [1].

| Constant $\alpha$ (St. Err.) | 1.45 *** (.40) |
|-----------------------------|----------------|
| Coefficient $i_1$ (St. Err.) | .180 *** (.03) |
| Coefficient $i_2$ (St. Err.) | −.001*** (.000) |
| $R^2$ (St. Err. of Estimate) | .33 (3.35) |
| $F$                           | 38.46***        |
| Total cases                  | 192            |

Note: Dependent variable is: Confirmed cases/population (%) of May 21, 2021. Explanatory variable is: doses of vaccines per 100 inhabitants on May 1, 2021.

Significance: *** p-value < 0.001.

### 4. Discussion and policy implications

The findings of the study here reveal that optimal level of vaccination is associated with the evolution of COVID-19 pandemic wave: a vaccination in the initial phase of pandemic wave has a lower optimal level of doses administered per 100 inhabitants to support the reduction of infected individuals, but the growth of pandemic wave moves up the optimal level of vaccines from 46.75 (in March 2021) to about 90 doses of vaccines in May 2021. This study also reveals that high levels of vaccination can reduce case fatality ratios and mortality rates of COVID-19 associated with other factors of health, environmental and economic system.

This study suggests that the optimal strategy and policy response to pandemic crisis are a rapid vaccination rollout to reduce timely numbers of infected individuals and deaths, before the takeoff of pandemic wave. These results may be interpreted through the lens of different studies that focus on many factors contributing to the success of implementing a rapid roll out of COVID-19 vaccination for reducing confirmed cases and negative social impact (Coccia, 2021a, 2021e, 2022). In fact, Sim et al. (2021) compare the COVID-19 pandemic in Israel and the UK, showing the importance of factors influencing the early days of the rollout of vaccination. Rosen et al. (2021) indicate three groups of facilitating factors the success of vaccination plan in Israel:

- extrinsic factors to health care (small size in terms of both area and population), a relatively young population, warm weather in December 2020, a centralized national system of government, and well-developed infrastructure for implementing prompt responses to large-scale national emergencies
- specific factors of the health-system, such as the organizational, IT and logistic capacities of community-based health care providers, the availability of well-trained cadre, a tradition of effective cooperation between government, health plans, hospitals, and emergency care providers, particularly during national emergencies; and effective tools and decision-making frameworks to support vaccination campaigns
- finally, specific factors to the COVID-19 vaccination effort: the mobilization of special government funding for vaccine purchase and distribution, timely contracting for a large amount of vaccines for population, the use of simple, clear and easily criteria for determining who had priority for receiving vaccines in the early phases of the distribution process, demanding cold storage requirements of the Pfizer-BioNTech COVID-19 vaccines, and outreach efforts to...
encourage people to sign up for vaccinations and then show up to get vaccinated (cf., McKee and Rajan, 2021).

In general, optimal strategies to pandemic shocks should be based on a strong public governance driven by adequate and effective leadership that engages with the communities and adjusts to population needs (Williams et al., 2020). In fact, good governance can support the preparedness of nations for performing efficient campaigns of vaccination to reduce infections, mortality, morbidity, mental stress among the population and support economic recovery (Ardito et al., 2021; Coccia, 2017a, 2018a, 2019, 2021a, 2021f, 2021g, 2022; (Coccia, 2021l), Coccia and Bellitto, 2018; Coccia and Benati, 2018; Kluge et al., 2020). The public governance supporting efficient plans of vaccination is not limited to health system, but it involves other functions of public administration to work properly for strengthening health, economic and social systems (Sagan et al., 2020). As a matter of fact, effective crisis management of COVID-19 pandemic, supported by multi-level governance, should implement timely vaccine programmes to achieve, whenever possible, the goal of proposed scenarios (Abaza, 2020; Anttiroiko, 2021; Coccia, 2021a, 2021f; DeRoo et al., 2020; Frederiksen et al., 2020; Harrison and Wu, 2020; Ritchie et al., 2020, 2020a). Nevertheless, the optimal level of vaccination in the initial phase of pandemic has to face distribution and allocation hurdles, and in the presence of delays, governments have to cope with changes into the equation of herd-immunity with a strategy of vaccination directed to increase the thresholds of immunization in population to reduce infected individuals and negative effects in society (Callaway, 2021; Dooling et al., 2020; Vignesh et al., 2020). In fact, the study here clearly shows that a delay of effective vaccination plan from March to May 2021, considering the evolutionary growth of pandemic wave, it moves forward the optimal threshold between countries from about 47 to 90 doses of vaccines per 100 people to trigger the reduction of the transmission dynamics of COVID-19 (Buss et al., 2021; ECDC, 2021; Mallapaty, 2021; Whittaker et al., 2021). In short, the timely achievement of the optimal threshold of doses administered is a basic aspect of crisis management, because a quickly and thoroughly vaccination plan can constrain transmission dynamics and consequential socioeconomic issues (Akamatsu, 2021; Byun et al., 2021; Liu et al., 2021). Engelbrecht and Scholes (2021) argue that if effective strategies of vaccination have delayed, the progress of pandemic wave may generate additional health and socioeconomic issues. Overall, then, the policy response based on an optimal level of vaccination, according to suggested scenarios, is a significant challenge associated with manifold socio-cultural and political-administrative factors, and enormous public investments in health system of countries (Ethgen et al., 2018; Coccia, 2017b, 2019, 2021g, 2022). Hence, countries can adequately prepare to prevent, detect and respond to both epidemics and pandemics, over the next ten years, with a better governance, innovative partnerships, high public investments, and efficient utilization of economic resources in health and other sectors (U.S. Department of Health and Human Services, 2021).

### Table 5
Negative effects of COVID-19 between countries having doses of vaccine below or above the optimal (estimated) level, used as cut-off point.

| Variables                              | Scenario A | Scenario B | Scenario C |
|----------------------------------------|------------|------------|------------|
| **Confirmed Cases/population %**       | Below      | Above      | Below      |
|                                        | 4.15       | 5.94       | 3.88       |
|                                        | Average    |            |            |
|                                        | 5.94       | 8.41       | 7.74       |
| **Case Fatality Ratios (CFR) %**       | Below      | Above      | Below      |
|                                        | 1.94       | 0.50       | 1.84       |
|                                        | Average    |            |            |
|                                        | 67.90      |            | 67.90      |
| **Mortality per 100 000 people**       | Below      | Above      | Below      |
|                                        | 75.00      | 32.74      | 41.11      |
|                                        | Average    |            |            |
|                                        | 65 495 630.45 | 51 009 497.76 | 51 777 286.42 |
| **Population**                         | Below      | Above      | Below      |
|                                        | 6 401 920.67 | 6 401 920.67 | 6 642 840.00 |

Fig. 1. Relation of confirmed cases/population (%) on doses of vaccines from March to May 2021 between countries based on quadratic model [1].
5. Conclusions and prospects

COVID-19 and future epidemics of novel viruses pose, more and more, a serious threat to security and public health of nations. An influenza pandemic, similar to COVID-19, can occur at any time with little warning; any delay in detecting a novel influenza strain; sharing of influenza virus samples; and in developing, producing, distributing, or administering a therapeutic or vaccine could result in significant additional morbidity and mortality, and deterioration of socioeconomic systems (Coccia, 2021, 2021e; Huang et al., 2021).

This study suggests that efficient strategies of vaccination have to be rapid and responsive in the initial phase of COVID-19 pandemic wave for reducing the negative impact of novel viral agent in society. These results here can help policymakers to design satisfying goals to cope with current pandemic applying effective vaccination strategies to prevent and/or cope with future outbreaks of the COVID-19 and similar epidemics. The most important policy implications of findings here are that, though high vaccination efforts of most advanced countries worldwide, the theoretical threshold for vanquishing COVID-19 seems to be out of reach at global level (in the medium run) because of the inequality in the distribution of vaccines, the uncertainty if and how new vaccines prevent or not the transmission, the duration of immunity in vaccinated people, hesitancy of people to vaccination and new variants that modify the herd-immunity equation and transmission dynamics (cf., Aschwanden, 2020, 2021). In fact, on November 2021 about 52% of the world population has received at least one dose of a COVID-19 vaccine and in poor countries a mere 5% of people have received at least one dose (Our World in Data, 2021).

Although this study has provided interesting results, that are of course tentative, it has several limitations. First, a limitation of the study is the lack of data about doses administered and total vaccinations in manifold countries, mainly in the spring season of the year 2021, also for the difficulty of production and distribution of COVID-19 vaccines worldwide and transmission of data and information. Second, not all the possible confounding factors that affect the efficacy of vaccination are taken into consideration (such as, length of lockdown, mitigation measures, etc.) and in future these factors deserve to be controlled for supporting results here. Third, the lack of integration of data with age of vaccinated people (the priority given in many countries to elderly sub-

countries. Finally, the estimated relationships in this study focus on variables in specific months (based on recent data available) but an extension of period under study is needed in future development of the research here. Thus, generalizing the results of this research should be done with caution. Future research should consider new data, when available, and when possible, to examine also other variables between countries to explain dynamic relationships under study over time and space. Despite these limitations, the results presented here suggest the critical aspect of the relationship between the evolution of pandemic wave and timing of the vaccination rollout to achieve the goal of optimal threshold of vaccination at national (and global) level for reducing negative effects of pandemic crisis in society. However, there is need for much more detailed research in these topics and this study encourages further investigations for supporting optimal strategies of vaccination, using lessons learned of COVID-19, also considering the temporal interaction between the evolution of pandemic wave and vaccination plan. To conclude, different factors between countries that are not only parameters related to medicine but also to other sciences can improve the preparedness of countries for an effective and a rapid roll out of vaccination to control negative impact of pandemic crisis on public health, economy and society.

Author’s contributions

Single author, Mario Coccia.

Declaration of competing interest

The author, Mario Coccia, declares that he has no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. List of countries \( N = 192 \)

| Countries 1-46 | Countries 47-92 | Countries 93-138 | Countries 139-184 | Countries 185-192 |
|----------------|----------------|----------------|----------------|----------------|
| Afghanistan    | Danimarca      | Kuwait         | Qatar          | Uruguay        |
| Albania        | Diamond Princess| Laos           | Regno Unito    | Uzbekistan     |
| Algeria        | Dominicana     | Lesotho        | Republica Ceca | Vanuatu        |
| Andorra        | Ecuador        | Lettonia       | Republica Centroaficana | Venezuela |
| Angola         | Egitto         | Libano         | Republica democratica del Congo | Vietnam |
| Antigua e Barbuda | El Salvador | Liberia        | Republica Dominicana | Yemen       |
| Arabia Saudita | United Arab Emirates | Libia       | Romania        | Zambia         |
| Argentina      | Eritrea        | Liechtenstein  | Ruanda         | Zimbabwe       |
| Armenia        | Estonia        | Lithuania      | Russia         |                |
| Australia      | Etiopia        | Luxemburgo     | Saint Kitts and Nevis |       |
| Austria        | Figi           | Macedonia del Nord | Saint Lucia |                |
| Azerbaijan     | Filipine       | Madagascar     | Saint Vincent e Grenadine |       |
| Bahamas        | Finlandia      | Malawi         | Samoa          |                |
| Bahrain        | Francia        | Maldives       | San Marino     |                |
| Bangladesh     | Gabon          | Malesia        | Sao Tome and Principe |       |
| Barbados       | Gambia         | Mali           | Senegal        |                |
| Belgio         | Georgia       | Malta          | Serbia         |                |
| Belize         | Germania       | Marocco        | Seychelles     |                |
| Benin          | Ghana          | Mauritania     | Sierra Leone   |                |
| Bhutan         | Gianaica       | Mauritius      | Singapore      |                |
| Bielorussia    | Giappone      | Messico        | Siria          |                |

(continued on next page)
Appendix. A supplemental data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.envres.2021.112314.

References

- Abbas, J., 2020. COVID-19 and mRNA vaccines-first large test for a new approach. J. Am. Med. Assoc. 324 (12), 1125–1127. https://doi.org/10.1001/jama.2020.16866.

- Abuza, Z., 2020. Explaining Successful (And Unsuccessful) COVID-19 Responses in Southeast Asia. Retrieved. The Diplomat. https://thediplomat.com/2020/04/explaining-successful-and-unsuccessful-covid-19-responses-in-southeast-asia/. (Accessed 7 July 2020).

- Akamatı, T., Nagea, T., OsaWA, M., Satsuoka, K., Sakai, T., Mizutani, D., 2021. Model-based analysis on social acceptability and feasibility of a focused protection strategy against the COVID-19 pandemic. Sci. Rep. 11 (1) https://doi.org/10.1038/s41598-021-18360-9, 2021.

- Aldila, D., Samiadji, B.M., Simorangkir, G.M., Khosnaw, S.H.A., Shahzad, M., 2021. Technological exaptation and crisis management: evidence from COVID-19 outbreaks. R D Manag. 51 (4), 298–302. https://doi.org/10.1111/radm.12455. Special Issue: Providing solutions in emergencies: R&D and innovation management during Covid-19 Part-2, September 2021.

- Ahmad, U., Cabreros, C., Mal, J., Ballesteros Jr., F., Sillanpää, E., 2021. Novel coronavirus disease 2019 (COVID-19) pandemic: from healthcare to social states, and innovation. Int. J. Public Sect. 45 (4), 501. https://doi.org/10.1038/d41586-021-00121-z.

- Anand, U., Cabreros, C., Mal, J., Ballesteros Jr., F., Sillanpää, E., 2021. Novel coronavirus disease 2019 (COVID-19) pandemic: from healthcare to social states, and innovation. Int. J. Public Sect. 45 (4), 501. https://doi.org/10.1038/d41586-021-00121-z.

- Anser, M.K., Yousaf, Z., Khan, M.A., Voo, X.H., Nassani, A.A., Alotaibi, S.M., Abro, M., 2021. International trade as critical parameter of COVID-19 spread that outclasses demographic, economic, environmental, and pollution factors. Environ. Res. 201 https://doi.org/10.1016/j.envres.2021.111514, ISSN 0013-9531. Article number 111514, PII S0013-9531(21)00808-2. 2021.

- Antón, M.J., Vaznau, Z., Khan, M.A., Voo, X.H., Nassani, A.A., Alotaibi, S.M., Abro, M., 2021. Are coincidences with COVID-19 and influenza low or underreported? An observational study examining current published literature including three new unpublished cases. J. Med. Virol. 92 (11), 2489–2497. https://doi.org/10.1002/jmv.26167.

- Antony, S.J., Almahbouth, N.K., Heydemann, E.L., 2020. Are coincidences with COVID-19 and influenza low or underreported? An observational study examining current published literature including three new unpublished cases. J. Med. Virol. 92 (11), 2489–2497. https://doi.org/10.1002/jmv.26167.

- Aravindan, C., 2020. The false promise of herd immunity for COVID-19. Nature. Nov 587 (7832), 26–28. https://doi.org/10.1038/d41586-020-02948-4.PMID 33087872.

- Arvino, A., Antronico, N., 2020. Successful government responses to the pandemic: contextualizing national and urban responses to the COVID-19 outbreak in East and west. International Journal of E-Planning Research (IJERP), IGI Global 10 (2), 1–17.

- Ardito, L., Coccia, M., Messeni Pettazzelli, A., 2021. Technological exaptation and crisis management: evidence from COVID-19 outbreaks. R D Manag. 51 (4), 298–302. https://doi.org/10.1111/radm.12455. Special Issue: Providing solutions in emergencies: R&D and innovation management during Covid-19 Part-2, September 2021.

- Ashchwanden, C., 2020. The false promise of herd immunity for COVID-19. Nature. Nov 587 (7832), 26–28. https://doi.org/10.1038/d41586-020-02948-4.PMID 33087872.

- Avolio, V., 2021. Novel coronavirus disease 2019 (COVID-19) pandemic: a critical perspective. Int. J. Innov. Technol. Manag. 18 (1) https://doi.org/10.1504/IJITM.2015.074642.

- Coccia, M., 2017. Disruptive firms and industrial change. J. Econ. Soc. Thought 4 (4), 437–450. https://doi.org/10.1453/jest.v4i4.1511.

- Coccia, M., 2017a. Varieties of capitalism’s theory of innovation and a conceptual integration with leadership-oriented executives: the relation between typologies of executive, technological and socioeconomic performances. Int. J. Public Sect. Perform. Manag. 3 (2), 148–166. https://doi.org/10.1057/ijpspm.2017.084672.
Our World in Data, 2021. Coronavirus (COVID-19) Vaccinations - Statistics and Research - Our World in Data. https://ourworldindata.org/covid-vaccinations. (Accessed 19 October 2021). Accessed.

Prieto Curiel, R., González Ramírez, H., 2021. Vaccination strategies against COVID-19 and the diffusion of anti-vaccination views. Sci. Rep. 11 (1), 6626.

Randolph, H.E., Barreiro, L.B., 2020. Herd immunity: understanding COVID-19. Immunity 52, 737–741.

Redwan, E.M., 2021. COVID-19 pandemic and vaccination build herd immunity. Eur. Rev. Med. Pharmacol. Sci. 25 (2), 577–579. https://doi.org/10.26355/eurrev_202101_24613.

Ritchie, H., Mathieu, E., Rodríguez-Guirao, L., Appel, C., Giattino, C., Ortiz-Ospina, E., Hasell, J., Macdonald, B., Beltekian, D., Roser, M., 2020a. Coronavirus pandemic (COVID-19). Published online at OurWorldInData.org. Retrieved from https://ourworldindata.org/coronavirus.

Randolph, H.E., Barreiro, L.B., 2020. Herd immunity: understanding COVID-19. Immunity 52, 737–741.

Redwan, E.M., 2021. COVID-19 pandemic and vaccination build herd immunity. Eur. Rev. Med. Pharmacol. Sci. 25 (2), 577–579. https://doi.org/10.26355/eurrev_202101_24613.

Ritchie, H., Matièu, E., Rodés-Guirao, L., Appel, C., Giattino, C., Ortiz-Ospina, E., Hasell, J., Macdonald, B., Beltekian, D., Roser, M., 2020a. Coronavirus pandemic (COVID-19). Published online at OurWorldInData.org. Retrieved from https://ourworldindata.org/coronavirus.

Ritchie, H., Ortiz-Ospina, E., Beltekian, D., Mathieu, E., Hasel, J., Macdonald, B., Giattino, C., Roser, M., 2020. Policy Responses to the Coronavirus Pandemic. Our World in Data, Statistics and Research. Retrieved. https://ourworldindata.org/policy-responses-covid. (Accessed 7 July 2020).

Rosen, B., Waitzberg, R., Israeli, A., 2021. Israel’s rapid rollout of vaccinations for COVID-19. Isr. J. Health Pol. Res. (1), 6.

Rossman, H., Shilo, S., Meir, T., et al., 2021. COVID-19 dynamics after a national immunization program in Israel. Nat. Med. https://doi.org/10.1038/s41591-021-01337-2, 2021.

Sagan, A., Thomas, S., McKee, M., Karanikolos, M., Azzopardi-Muscat, N., de la Mata, I., Figueras, J., 2020. COVID-19 and health systems resilience: lessons going forwards. Eurohealth 26 (2).

Seligman, B., Ferrana, M., Bloom, D.E., 2021. Social determinants of mortality from COVID-19: a simulation study using NHANES. PLoS Med. 18 (1), e1003490 https://doi.org/10.1371/journal.pmed.1003490.

Sim, F., 2021. Early Covid-19 vaccination rollout: a commentary from England. Isr. J. Health Pol. Res. 10 (1), 18.

U.S. Department of Health & Human Services, 2021. Public Health Emergency-Executive Summary (accessed March 2021). https://www.phe.gov/Preparedness/planning/nivms/Pages/executive-summary.aspx.

Vignesh, R., Shankar, E.M., Vels, V., Thyagarajan, S.P., 2020. Is herd immunity against SARS-CoV-2 a silver lining? Front. Immunol. 11, 586781 https://doi.org/10.3389/fimmu.2020.586781.

Vinceti, M., Filippini, T., Rothman, K.J., Di Federico, S., Orsini, N., 2021. SARS-CoV-2 infection incidence during the first and second COVID-19 waves in Italy. Environ. Res. 197, 111097 https://doi.org/10.1016/j.envres.2021.111097.

Wilson, N., Kvalevig, A., Barnard, L., et al., 2020. Case-fatality risk estimates for COVID-19 calculated by using a lag time for fatality. Emerg. Infect. Dis. 26 (6), 1339–1441. https://doi.org/10.3201/eid2606.200320.

Zhang, B., Zhou, X., Qiu, Y., Song, Y., Feng, F., Feng, J., et al., 2020. Clinical characteristics of 82 cases of death from COVID-19. PLoS One 15 (7), e0235458. https://doi.org/10.1371/journal.pone.0235458.